



68/1623  
3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAR 07 2002

TECH CENTER 1600/2900

Applicants: Gosselin, *et al.*

Serial No.: 10/022,276

Filed: 14-Dec-2001

Title: B-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B Virus

Assistant Commissioner for Patents  
Washington, DC 20231

February 25, 2002


**Transmittal of Information Disclosure Statement**

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,

  
Josephine Young  
Reg. No. 48,308

KING & SPALDING  
191 Peachtree Street  
Atlanta, GA 30303  
404-572-2882 (Telephone)  
404-572-5145 (Facsimile)



INFORMATION DISCLOSURE STATEMENT  
Docket No. 06171.105005  
10/022,276


RECEIVED

MAR 07 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as Express Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

  
\_\_\_\_\_  
Josephine Young

Date: February 25, 2002